CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

NCT03152708 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2017-09-21

No results posted yet for this study

Summary

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Conditions

Sponsors & Collaborators

  • CANbridge Life Sciences Ltd.

    lead INDUSTRY

Principal Investigators

  • Jinsong Wu, MD · Huashan Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2017-12-01
Completion
2017-12-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03152708 on ClinicalTrials.gov